NCD20.22 ETHYLENEDIAMINE-TETRA-ACETIC (EDTA) CHELATION THERAPY

FOR TREATMENT OF ATHEROSCLEROSIS

 

 

Effective Date of this Version

 

• This is a longstanding national coverage determination.

• The effective date of this version has not been posted.

 

 

Benefit Category

 

• Physicians' Services

• Note: This may not be an exhaustive list of all applicable Medicare benefit categories for this item or service.

 

 

Indications and Limitations of Coverage

 

• The use of EDTA as a chelating agent to treat atherosclerosis, arteriosclerosis, calcinosis, or similar generalized condition NOT listed by the FDA as an approved use is not covered. Any such use of EDTA is considered experimental.

 

 

Cross Reference

• See §20.21 of the NCD Manual.

 

 

Medicare NCD Link